{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:34:24Z","timestamp":1760056464120,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck &amp; Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.diagmicrobio.2023.115904","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T18:09:16Z","timestamp":1674756556000},"page":"115904","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative in vitro antipseudomonal activity of ceftolozane\/tazobactam against Pseudomonas aeruginosa isolates from children with cystic fibrosis"],"prefix":"10.1016","volume":"105","author":[{"given":"Neena","family":"Kanwar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan A.","family":"Pence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rangaraj","family":"Selvarangan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0001","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00138-18","article-title":"Cystic fibrosis and Pseudomonas aeruginosa: the host-microbe interface","volume":"32","author":"Malhotra","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0002","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S1526-0550(02)00003-3","article-title":"Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistence","volume":"3","author":"Davies","year":"2002","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0003","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fped.2020.00173","article-title":"Ceftolozane\/Tazobactam for treating children with exacerbations of cystic fibrosis due to Pseudomonas aeruginosa: a review of available data","volume":"8","author":"Garazzino","year":"2020","journal-title":"Front Pediatr"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0004","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.diagmicrobio.2018.05.002","article-title":"Ceftolozane\/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients","volume":"92","author":"Finklea","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0005","doi-asserted-by":"crossref","first-page":"ofy158","DOI":"10.1093\/ofid\/ofy158","article-title":"In Vitro Activity of Ceftolozane\/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates","volume":"5","author":"Forrester","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0006","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diagmicrobio.2015.04.012","article-title":"Microbiological activity of ceftolozane\/tazobactam, ceftazidime, meropenem, and piperacillin\/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis","volume":"83","author":"Kuti","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0007","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.1021\/acs.jmedchem.5b01698","article-title":"Novel strategies for the treatment of Pseudomonas aeruginosa infections","volume":"59","author":"Wagner","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0008","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1128\/AAC.01737-10","article-title":"Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes","volume":"55","author":"Sader","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0009","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14787210.2018.1447381","article-title":"Ceftolozane\/tazobactam: place in therapy","volume":"16","author":"Giacobbe","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0010","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/jac\/dkx136","article-title":"Activity of ceftolozane\/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0011","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jac\/dkx009","article-title":"Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15)","volume":"72","author":"Pfaller","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00465-17","article-title":"Ceftolozane-tazobactam activity against Pseudomonas aeruginosa clinical isolates from U.S. hospitals: report from the PACTS antimicrobial surveillance program, 2012 to 2015","volume":"61","author":"Shortridge","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0013","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijid.2021.09.064","article-title":"Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015-2018","volume":"112","author":"Pfaller","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0014","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jgar.2020.04.017","article-title":"Ceftolozane-tazobactam and ceftazidime-avibactam activity against \u03b2-lactam-resistant Pseudomonas aeruginosa and extended-spectrum \u03b2-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres","volume":"22","author":"Hirsch","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0015","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1128\/AAC.02969-15","article-title":"Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates","volume":"60","author":"Buehrle","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0016","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3343\/alm.2017.37.2.174","article-title":"Susceptibility of ceftolozane-tazobactam and ceftazidime-avibactam against a collection of \u03b2-lactam-resistant gram-negative bacteria","volume":"37","author":"Gonzalez","year":"2017","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0017","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00875-17","article-title":"Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds","volume":"61","author":"Grupper","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0018","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01858-17","article-title":"Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"year":"2022","series-title":"Performance standards for antimicrobial susceptibility testing","key":"10.1016\/j.diagmicrobio.2023.115904_bib0019"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0020","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13756-021-00933-8","article-title":"Real-world use of ceftolozane\/tazobactam: a systematic literature review","volume":"10","author":"Puzniak","year":"2021","journal-title":"Antimicrobial Resistance & Infection Control"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0021","doi-asserted-by":"crossref","first-page":"S528","DOI":"10.1093\/ofid\/ofx163.1376","article-title":"Ceftolozane\/tazobactam dose evaluation for pediatric subjects with complicated intra-abdominal infection and complicated urinary tract infection","volume":"4","author":"Larson","year":"2017","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105891","article-title":"Ceftolozane\/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: a systematic review of its efficacy and safety for off-label indications","volume":"55","author":"Maraolo","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0023","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1128\/AAC.00705-16","article-title":"Multidrug-resistant Pseudomonas aeruginosa infection in a child with cystic fibrosis","volume":"60","author":"Ang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0024","first-page":"215","article-title":"Ceftolozane\/tazobactam: a novel antipseudomonal cephalosporin and \u03b2-lactamase-inhibitor combination","volume":"6","author":"Hong","year":"2013","journal-title":"Infection and drug resistance"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0025","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1128\/AAC.00705-16","article-title":"Multidrug-resistant Pseudomonas aeruginosa infection in a child with cystic fibrosis","volume":"60","author":"Ang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0026","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jgar.2018.03.002","article-title":"In vitro antimicrobial activity of ceftolozane\/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis","volume":"14","author":"Gramegna","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0027","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/j.1469-0691.2010.03130.x","article-title":"Activity of the new cephalosporin CXA-101 (FR264205) against <em>Pseudomonas aeruginosa<\/em>isolates from chronically-infected cystic fibrosis patients","volume":"16","author":"Zamorano","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0028","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2023.115904_bib0029","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jac\/dkx424","article-title":"Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa","volume":"73","author":"Fraile-Ribot","year":"2018","journal-title":"J Antimicrob Chemother"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889323000147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889323000147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:58:21Z","timestamp":1760003901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889323000147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0732889323000147"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2023.115904","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative in vitro antipseudomonal activity of ceftolozane\/tazobactam against Pseudomonas aeruginosa isolates from children with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2023.115904","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115904"}}